ImmunityBio's Legal and Commercial Timelines Diverge Under Scrutiny

ImmunityBio finds itself navigating a stark divergence between its commercial success and a burgeoning legal crisis. While the biotech firm reports record-breaking revenue for its cancer drug Anktiva, it faces a coordinated wave of investor lawsuits triggered by a regulatory rebuke, creating a volatile mix for shareholders.

The legal storm stems from a U.S. Food and Drug Administration warning letter, dated March 13, 2026, which became public on March 24. The FDA criticized a television commercial and a podcast appearance by Executive Chairman Dr. Patrick Soon-Shiong, alleging the materials misleadingly suggested Anktiva could "cure and even prevent all cancers." The market reaction was swift and severe: the stock price plummeted 21% in a single day, closing at $7.42 and erasing nearly $2 billion in market capitalization.

In the wake of this disclosure, a flurry of law firms have initiated class action suits. By April 21, five firms—Pomerantz LLP, Schall Law Firm, Faruqi & Faruqi, Kessler Topaz Meltzer & Check, and the Gross Law Firm—had published coordinated investor alerts. The lawsuits, filed in the U.S. District Court for the Central District of California, allege violations of the Securities Exchange Act of 1934, claiming the company overstated Anktiva's capabilities and omitted material risks. The case is proceeding under the docket number Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.

Investors who suffered losses between January 19 and March 24, 2026, have until May 26, 2026, to apply for lead plaintiff status, a role that will significantly influence the litigation's strategy.

Amid this legal pressure, ImmunityBio's underlying business shows remarkable strength. The company posted preliminary product revenue of $44.2 million for the first quarter of 2026, a staggering 168% increase year-over-year and a 15% sequential gain from the final quarter of 2025. For the full year 2025, the company reported $113 million in revenue, representing a 700% surge from 2024. The firm's cash position remains robust, with liquidity of approximately $381 million as of the end of March, bolstered by a recent $75 million expansion of its financing agreement with Oberland Capital, bringing the total facility to $375 million.

Commercial milestones continue to accumulate. On April 21, ImmunityBio announced the first commercial availability of Anktiva in Saudi Arabia for the treatment of metastatic non-small cell lung cancer in combination with an immune checkpoint inhibitor—a global first for this indication. Local partners Biopharma and Cigalah Healthcare are facilitating the launch, with initial patients already identified for lung and bladder cancer treatments. Anktiva initially received FDA approval in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer.

The company has taken steps to address the FDA's concerns, submitting a comprehensive response on April 6. It removed the implicated podcast from its website, requested its deletion from third-party platforms, and stated the criticized TV spot never aired. Enhanced promotional review processes and external regulatory monitoring have also been implemented.

Analyst perspectives reflect this dichotomy. Despite the legal overhang, D. Boral Capital reaffirmed its Buy rating on April 21 with a $23 price target, implying an upside of roughly 180%. Analyst Jason Kolbert cited the commercial momentum of Anktiva. The broader consensus among seven Wall Street analysts remains a "Moderate Buy," with an average twelve-month price target of $14.40; six recommend buying the stock, while one advises selling.

The coming weeks will be critical as the May 26 lead plaintiff deadline passes, setting the stage for the next phase of legal proceedings. The court's eventual assessment of the allegations will determine whether the weight of the lawsuits continues to overshadow the company's fundamental growth narrative.

Ad

ImmunityBio Stock: New Analysis - 23 April

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...